Press Releases
BOSTON--(BUSINESS WIRE)--AVS, an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease with its PIVL™ therapy, announced today that it closed an additional $8.8 million in new financing, bringing its Series B round to $28.8 million total.
BOSTON--(BUSINESS WIRE)--AVS, an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease with its PIVL™ therapy, announced today that it raised $20 million in Series B financing. The new funding will accelerate clinical trial timelines for the company’s device for peripheral application in pulsatile intravascular lithotripsy (PIVL) cases and advance development and preclinical work on a PIVL device for coronary cases.
Pulsatile Intravascular Lithotripsy shows promise as new treatment therapy for severely calcified vessels
ANN ARBOR, Mich. – September 15, 2022, -- AVS, an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease with its PIVL™ therapy, today announced enrollment, successful treatment, and positive 30-day follow up data of the first patients in the POWER PAD I clinical trial. AVS is only the second company to conduct a first-in-human study in the rapidly growing intravascular lithotripsy space.
In The News
AVS announced the initiation of enrollment, successful treatment, and positive 30-day follow up data in the POWER PAD I clinical trial.
https://evtoday.com/news/avs-begins-power-pad-i-trial-of-pulse-ivl-ther…